Research programme: recombinant glucosylceramidase - JCR Pharmaceuticals/GlaxoSmithKline

Drug Profile

Research programme: recombinant glucosylceramidase - JCR Pharmaceuticals/GlaxoSmithKline

Alternative Names: JR-101

Latest Information Update: 12 Aug 2016

Price : $50

At a glance

  • Originator JCR Pharmaceuticals
  • Developer GlaxoSmithKline KK; JCR Pharmaceuticals
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gaucher's disease

Most Recent Events

  • 12 Aug 2016 Preclinical development is ongoing for Gaucher's disease in Japan (JCR Pharmaceuticals pipeline, August 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gaucher's-disease in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top